http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박일구,박철진,신지혜,김진화,김상용,배학연 朝鮮大學校 附設 醫學硏究所 2008 The Medical Journal of Chosun University Vol.33 No.1
인슐린 자가면역 증후군은 항체에 결합되어 있던 인슐린이 혈당정도와 관계없이 유리됨으로써 저혈당이 야기되는 질환으로, 인슐린종 등과 감별을 필요로 하는 질환이다. 저자들은 고인슐린혈증과 인슐린 자가항체가 양성이면서 공복검사상에서 저혈당이 유발되며 경구 포도당 부하 검사에서 저혈당이 유발된 자가면역성 저혈당증을 경험하였기에 문헌고찰과 함께 보고하는 바이다. Autoimmune hypoglycemia is one of the rare causes of hypoglycemia, and characterized by hyperinsulinemia. Insulin autoimmune syndrome is characterized by insulin autoantibody, hyperinsulinemia, and fasting hypoglycemia without previous insulin immunization. Insulin autoimmune syndrome is usually related to autoimmune disease such as Graves' disease and to previous exposure to drugs. This syndrome is a self-limited disorder. The hypoglycemia was treated with prednisolone and the patient recovered from this. Recently we experinenced two cases of insulin autoimmune syndrome that developed symptomatic hypoglycemia during both the fasting and oral glucose tolerance test. Here in, We present those cases with a review of the literature.
Choi, Eun-Ji,Lee, Je-Hwan,Lee, Jung-Hee,Park, Han-Seung,Ko, Sun-Hye,Hur, Eun-Hye,Moon, Juhyun,Goo, Bon-Kwan,Kim, Yeonhee,Seol, Miee,Lee, Young-Shin,Kang, Young-Ah,Jeon, Mijin,Woo, Ji Min,Lee, Kyoo-Hyu Elsevier 2018 Leukemia research Vol.68 No.-
<P><B>Abstract</B></P> <P>This retrospective analysis compared anthracyclines (as part of an induction regimen) in 128 newly diagnosed <I>FLT3</I>-ITD-mutated AML patients. Induction regimens comprised high-dose daunorubicin (HD-DN; 90 mg/m<SUP>2</SUP>/d × 3d; n = 44), standard-dose daunorubicin (SD-DN; 45 mg/m<SUP>2</SUP>/d × 3d; n = 51), or idarubicin (IDA; 12 mg/m<SUP>2</SUP>/d × 3d; n = 33) in combination with cytarabine (100–200 mg/m<SUP>2</SUP>/d × 7d). Fifty-three patients showing persistent leukemia on interim bone marrow examination received a second course of induction chemotherapy comprising 2 days of daunorubicin (45 mg/m<SUP>2</SUP>/d) or IDA (8 or 12 mg/m<SUP>2</SUP>/d) in addition to 5 days of cytarabine. Complete remission (CR) rates were 77.3%, 56.9%, and 69.7% for HD-DN, SD-DN, and IDA, respectively (<I>P</I> = 0.101; HD-DN <I>vs.</I> SD-DN, <I>P</I> = 0.036; HD-DN <I>vs.</I> IDA, <I>P</I> = 0.453; IDA <I>vs.</I> SD-DN, <I>P</I> = 0.237). The HD-DN showed higher overall survival (OS) and event-free survival (EFS) than SD-DN and IDA: the differences between HD-DN and SD-DN (<I>P</I> = 0.009 for OS and <I>P</I> = 0.010 for EFS) were statistically significant.</P> <P>Results of <I>in vitro</I> studies using <I>FLT3</I>-ITD-mutated cell lines supported these findings. In conclusion, HD-DN improved the CR rate, OS, and EFS of <I>FLT3</I>-ITD-mutated AML patients. HD-DN also tended to yield better outcomes than IDA, though the difference was not significant. The superiority of HD-DN over IDA should be confirmed in future studies.</P> <P><B>Highlights</B></P> <P> <UL> <LI> <I>FLT3</I>-ITD-mutated AML patients benefited from high-dose daunorubicin. </LI> <LI> High-dose daunorubicin seems to yield better results than idarubicin. </LI> <LI> The results of <I>in vitro</I> studies support these findings. </LI> </UL> </P>